The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations

To explore the efficacy and safety of EGFR-TKI combined with thymosin therapy in advanced non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations. Patients confirmed as advanced NSCLC with active EGFR mutations were recruited from August 2008 to July 2018 retrospectively. Patient...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 659065
Main Authors Feng, Yongdong, Zhu, Guangkuo, Lang, Song, Hao, Ping, Li, Guanghui, Chen, Fanglin, Zhuo, Wenlei, Duan, Yuzhong, Zhang, Anmei, Chen, Zhengtang, Sun, Jianguo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.05.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To explore the efficacy and safety of EGFR-TKI combined with thymosin therapy in advanced non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations. Patients confirmed as advanced NSCLC with active EGFR mutations were recruited from August 2008 to July 2018 retrospectively. Patients treated with EGFR-TKI were classified as the EGFR-TKI group. And those received EGFR-TKI and thymosin therapy were designated as the EGFR-TKI plus thymosin group. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), tumor response and adverse effects. The median PFS was significantly longer in EGFR-TKI plus thymosin group than that in EGFR-TKI group (14.4 months . 9.2 months; HR=0.433, 95% CI 0.322 - 0.582, <0.0001). The median OS was also prolonged in EGFR-TKI plus thymosin group than that in EGFR-TKI group (29.5 months . 19.8 months; HR=0.430, 95% CI 0.319 - 0.580, <0.0001). The objective response rate in EGFR-TKI plus thymosin group and EGFR-TKI group were 60.0% versus 60.8% ( =0.918). The disease control rate was 96.9% in EGFR-TKI plus thymosin group and 97.7% in EGFR-TKI group ( =1.000). There were no significant differences in adverse effects between the two groups. The number of CD3 T cells in peripheral blood decreased significantly after treatment including both CD3 CD4 T and CD3 CD8 T subsets in EGFR-TKI group, but not in EGFR-TKI plus thymosin group. Combination of EGFR-TKI and thymosin can significantly prolong the PFS and OS compared with EGFR-TKI monotherapy without more adverse events, which offers a new strategy in clinic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Olivier Feron, Université catholique de Louvain, Belgium
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Reviewed by: Claudio Constantini, University of Perugia, Italy; Wenliang Li, University of Texas Health Science Center at Houston, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.659065